Hammond D W, Goepel J R, Aitken M, Hancock B W, Potter A M, Goyns M H
Department of Clinical Oncology, Royal Hallamshire Hospital, Sheffield, England.
Cancer Genet Cytogenet. 1992 Jul 1;61(1):31-8. doi: 10.1016/0165-4608(92)90366-g.
We describe cytogenetic analyses of cells derived from 40 non-Hodgkins lymphoma (NHL) node biopsies, 23 of which were from patients who had not been treated before biopsy. We noted that the chromosomes most frequently gained were X (32%), 12 (27%), and 3 (24%). Monosomies were much less common; loss of chromosome 13 (13.5%) was most frequent. Structural abnormalities primarily involved chromosomes 14 (70%), 1 (40.5%), 18 (38%), 6 (35%), and 17 (22%). Low-and high-grade disease showed similar patterns of structural changes; however, a markedly greater number of chromosome gains were associated with low-grade disease. Biopsy samples from patients who had previously been treated showed an increased frequency of structural abnormalities, as well as a significantly larger number of chromosome gains. The importance of these observations, particularly with regard to possible oncogene involvement in lymphoma evolution, is discussed.
我们描述了对40例非霍奇金淋巴瘤（NHL）淋巴结活检样本所获细胞进行的细胞遗传学分析，其中23例来自活检前未接受过治疗的患者。我们注意到，最常出现增益的染色体是X染色体（32%）、12号染色体（27%）和3号染色体（24%）。单体性则要少见得多；13号染色体缺失（13.5%）最为常见。结构异常主要累及14号染色体（70%）、1号染色体（40.5%）、18号染色体（38%）、6号染色体（35%）和17号染色体（22%）。低度和高度恶性疾病显示出相似的结构变化模式；然而，与低度恶性疾病相关的染色体增益数量明显更多。先前接受过治疗的患者的活检样本显示结构异常的频率增加，以及染色体增益数量显著增多。本文讨论了这些观察结果的重要性，特别是关于癌基因可能参与淋巴瘤演变方面的重要性。
